Updating your news feed...

NEWS EXPRESS is Nigeria’s leading online newspaper. Published by Africa’s international award-winning journalist, Mr. Isaac Umunna, NEWS EXPRESS is Nigeria’s first truly professional online daily newspaper. It is published from Lagos, Nigeria’s economic and media hub, and has a provision for occasional special print editions. Thanks to our vast network of sources and dedicated team of professional journalists and contributors spread across Nigeria and overseas, NEWS EXPRESS has become synonymous with newsbreaks and exclusive stories from around the world.


























Loading banners
Loading banners...


NAFDACDG, Prof Adeyeye
By ADEROGBA GEORGE
The National Agency for Food and Drugs Administration and Control (NAFDAC) has cautioned Nigerians against the use of the drug – Weight Rapid Loss Capsule.
The caution is contained in an alert with No. 049/2022, signed by NAFDAC’s Director-General, Prof. Mojisola Adeyeye, issued to the News Agency of Nigeria (NAN) on Sunday in Abuja.
Adeyeye stated that the drug has been found to have potential to cause cancer.
The NAFDAC boss added that result of laboratory analysis showed that the drug, manufactured by Ingi Oman, contain banned substance “phenolphthalein”, which the U.S. Food and Drug Administration recognised as unsafe.
She added that the capsule, being marketed as “the most effective weight loss supplement” and sold through social media platforms like Instagram, also contain microbial growth above permissible limits.
She stated that “phenolphthalein has been found to be toxic to genes, as it can cause damage or mutations in the DNA. Studies have also shown its potential carcinogenic risks.
“NAFDAC implores consumers to stop the purchase and use of the product.
“Members of the public in possession of the product should discontinue use or sale, and submit stock to the nearest NAFDAC office.”
Adeyeye encouraged healthcare professionals and consumers to report any adverse effect experienced with the use of the product to the nearest NAFDAC office.
Consumers are also advised to report adverse effect via pharmacovigilance@nafdac.gov.ng or E-reporting platforms available at www.nafdac.gov.ng.
The director-general urged the public to also report any incident concerning the use of the drug via the Med-safety application, which can be downloaded on android and IOS stores. (NAN)